Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00054639
Status:
COMPLETED
Last Update Posted:
2014-05-28
First Post:
2003-02-05
Brief Title:
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Waldenström Macroglobulinemia |
| Cutaneous B-cell Non-Hodgkin Lymphoma |
| Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue |
| Intraocular Lymphoma |
| Nodal Marginal Zone B-cell Lymphoma |
| Recurrent Adult Burkitt Lymphoma |
| Recurrent Adult Diffuse Large Cell Lymphoma |
| Recurrent Adult Diffuse Mixed Cell Lymphoma |
| Recurrent Adult Diffuse Small Cleaved Cell Lymphoma |
| Recurrent Adult Grade III Lymphomatoid Granulomatosis |
| Recurrent Adult Immunoblastic Large Cell Lymphoma |
| Recurrent Adult Lymphoblastic Lymphoma |
| Recurrent Grade 1 Follicular Lymphoma |
| Recurrent Grade 2 Follicular Lymphoma |
| Recurrent Grade 3 Follicular Lymphoma |
| Recurrent Mantle Cell Lymphoma |
| Recurrent Marginal Zone Lymphoma |
| Recurrent Small Lymphocytic Lymphoma |
| Small Intestine Lymphoma |
| Splenic Marginal Zone Lymphoma |
| Testicular Lymphoma |
Keywords: